Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype

[1]  S. Locarnini,et al.  Hepatitis B surface antigen quantification: Not what it seems on the surface , 2012, Hepatology.

[2]  Jia-Horng Kao,et al.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update , 2012, Hepatology International.

[3]  E. Keeffe,et al.  Review article: current antiviral therapy of chronic hepatitis B , 2011, Alimentary pharmacology & therapeutics.

[4]  P. Revill,et al.  HBV Genotypes: Relevance to Natural History, Pathogenesis and Treatment of Chronic Hepatitis B , 2011, Antiviral therapy.

[5]  C. Yeh,et al.  Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B , 2011, BMC Cancer.

[6]  J. Kao,et al.  The clinical implications of hepatitis B virus genotype: Recent advances , 2011, Journal of gastroenterology and hepatology.

[7]  H. Tillmann,et al.  Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: Hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern , 2010, Journal of medical virology.

[8]  H. Zhuang,et al.  Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/ nucleotide analogue treatment among Chinese chronic hepatitis B patients , 2010, Antiviral therapy.

[9]  P. Angus,et al.  Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B , 2010, Gut.

[10]  V. Wong,et al.  Hepatitis B Virus (HBV) Subgenotypes C2 and B2 Differ in Lamivudine- and Adefovir-Resistance-Associated Mutational Patterns in HBV-Infected Chinese Patients , 2010, Journal of Clinical Microbiology.

[11]  S. Lewin,et al.  Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers , 2010, Hepatology.

[12]  F. Zoulim,et al.  Hepatitis B virus resistance to nucleos(t)ide analogues. , 2009, Gastroenterology.

[13]  Y. Liaw,et al.  Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy , 2009, Antiviral therapy.

[14]  J. Yeon,et al.  Hepatitis B Viral Surface Mutations in Patients with Adefovir Resistant Chronic Hepatitis B with A181T/V Polymerase Mutations , 2009, Journal of Korean medical science.

[15]  C. Yeh,et al.  The Oncogenic Potential of Hepatitis B virus rtA181T/ Surface Truncation Mutant , 2008, Antiviral therapy.

[16]  Y. Liaw,et al.  Erratum: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update (Hepatology International 10.1007/s12072-008-9080-3) , 2008 .

[17]  N. Warner,et al.  The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound , 2008, Hepatology.

[18]  J. Kao,et al.  Genetic Variability of Hepatitis B virus and Response to Antiviral Therapy , 2008, Antiviral therapy.

[19]  D. Hasenclever,et al.  Should Treatment of Hepatitis B Depend on Hepatitis B virus Genotypes? A Hypothesis Generated from an Explorative Analysis of Published Evidence , 2008, Antiviral therapy.

[20]  S. Locarnini,et al.  SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B. , 2007, Antiviral research.

[21]  N. Warner,et al.  The L80I Substitution in the Reverse Transcriptase Domain of the Hepatitis B Virus Polymerase Is Associated with Lamivudine Resistance and Enhanced Viral Replication In Vitro , 2007, Antimicrobial Agents and Chemotherapy.

[22]  A. Berger,et al.  Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer? , 2007, Gut.

[23]  E. Hildt,et al.  Hepatitis B virus-induced oncogenesis. , 2007, World journal of gastroenterology.

[24]  V. Wong,et al.  Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma , 2004, Gut.

[25]  D. Lavanchy,et al.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.

[26]  Angeline Bartholomeusz,et al.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.

[27]  F. Chan,et al.  Hepatitis B Virus Genotype C Takes a More Aggressive Disease Course Than Hepatitis B Virus Genotype B in Hepatitis B e Antigen-Positive Patients , 2003, Journal of Clinical Microbiology.

[28]  H. Isom,et al.  Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine‐resistant HBV in vitro , 2003, Hepatology.

[29]  A. Lok,et al.  Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. , 2002, Gastroenterology.

[30]  D. Parkin,et al.  Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.

[31]  M. Manns,et al.  Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus , 2001, Antimicrobial Agents and Chemotherapy.

[32]  F. Zoulim,et al.  Management of treatment failure in chronic hepatitis B. , 2012, Journal of hepatology.

[33]  Kijeong Kim,et al.  Nucleotide change of codon 182 in the surface gene of hepatitis B virus genotype C leading to truncated surface protein is associated with progression of liver diseases. , 2012, Journal of hepatology.

[34]  C. Yeh.  Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy. , 2010, Antiviral therapy.